{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:39:48Z","timestamp":1791567588781,"version":"4.3.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006022","name":"Minist\u00e8re des Affaires Sociales, de la Sant\u00e9 et des Droits des Femmes","doi-asserted-by":"crossref","award":["no"],"award-info":[{"award-number":["no"]}],"id":[{"id":"10.13039\/501100006022","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011568","name":"Minist\u00e8re de la transition \u00e9cologique et solidaire","doi-asserted-by":"crossref","award":["no"],"award-info":[{"award-number":["no"]}],"id":[{"id":"10.13039\/501100011568","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Hypercholesterolemia is a major risk factor for cardiovascular diseases. However, its management in everyday clinical practice is often suboptimal. The aims of the Esteban study were to estimate the prevalence of hypercholesterolemia and to describe its management in France in 2015.<\/jats:p>\n            <jats:p>Esteban is a cross-sectional, publicly funded survey, representative of the French population. Data were collected using questionnaires and biological and clinical examinations in 3021 adults aged 18-74.<\/jats:p>\n            <jats:p>The lipid-lowering treatments were obtained by matching the individual data of the subjects included in the Esteban survey with data from the <jats:italic toggle=\"yes\">Syst\u00e8me national de donn\u00e9es de sant\u00e9<\/jats:italic>. Hypercholesterolemia was defined as either a low density lipoprotein cholesterol value higher than the goal set in the European Society of Cardiology\/European Atherosclerosis Society guidelines as a function of individual cardiovascular risk level, or at least 1 delivery of lipid-lowering treatment. Adherence was defined by the proportion of days covered by the lipid-lowering treatment in the 6 months preceding clinical examination. Prevalence of hypercholesterolemia in France was 23.3% (27.8% in men, 19.0% in women). Mean low density lipoprotein cholesterol was 3.38\u200ammol\/l in French participants. Among them, 7.2% were treated (8.5% of men, 5.8% of women), while 16.1% of adults went untreated (19.3% of men, 13.2% of women). Only 29.7% of secondary prevention adults had a delivery of lipid-lowering treatments in the 6 months preceding clinical examination. Fewer than 1 in 3 treated adults were adherent, i.e. more than 80% of days covered by a treatment. This proportion reached 37.4% in the high-risk group, with no significant difference of adherence in people with or without a personal history of cardiovascular disease in this group.<\/jats:p>\n            <jats:p>This study showed that hypercholesterolemia is a common metabolic disease in France, affecting 23.3% of the population. Lipid-lowering prescriptions diverged greatly from current recommendations, with less than a third of eligible patients being treated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023445","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T22:07:17Z","timestamp":1607638037000},"page":"e23445","source":"Crossref","is-referenced-by-count":27,"title":["Prevalence and management of hypercholesterolemia in France, the Esteban observational study"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4860-4279","authenticated-orcid":false,"given":"Jacques","family":"Blacher","sequence":"first","affiliation":[{"name":"Diagnosis and Therapeutic Center, Hotel Dieu; AP-HP; University Paris Descartes, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Gabet","sequence":"additional","affiliation":[{"name":"French Public Health Agency, Saint-Maurice"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Vall\u00e9e","sequence":"additional","affiliation":[{"name":"Diagnosis and Therapeutic Center, Hotel Dieu; AP-HP; University Paris Descartes, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Ferri\u00e8res","sequence":"additional","affiliation":[{"name":"Cardiology Department; INSERM UMR 1027; Toulouse University Hospital; 30159 Toulouse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[{"name":"Endocrinology, metabolism and cardiovascular prevention; E3\u200aM Institut and cardiometabolic IHU (ICAN) Piti\u00e9 Salp\u00eatri\u00e8re hospital, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[{"name":"Point M\u00e9dical and Cardiology Department, CHU Dijon-Bourgogne, Dijon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Oli\u00e9","sequence":"additional","affiliation":[{"name":"French Public Health Agency, Saint-Maurice"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Naghavi","year":"2017","journal-title":"Lancet"},{"key":"R2-20230916","first-page":"49","article-title":"Mortality data in France: the main causes of death in 2008 and trends since 2000","volume":"2","author":"Aouba","year":"2011","journal-title":"Bull Epidemiol Hebd"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980-2000","volume":"356","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease","volume":"322","author":"Pekkanen","year":"1990","journal-title":"N Engl J Med"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-115-9-687","article-title":"Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study","volume":"115","author":"Wong","year":"1991","journal-title":"Ann Intern Med"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/heartjnl-2018-314253","article-title":"Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease","volume":"105","author":"Akyea","year":"2019","journal-title":"Heart"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"e0228472","DOI":"10.1371\/journal.pone.0228472","article-title":"Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea","volume":"15","author":"Kim","year":"2020","journal-title":"PLoS One"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijcard.2020.06.059","article-title":"Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data","volume":"316","author":"Athyros","year":"2020","journal-title":"Int J Cardiol"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.acvd.2012.11.003","article-title":"Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study","volume":"106","author":"Bongard","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.lpm.2018.05.011","article-title":"The disturbing state of affairs of hypertension in France: a replica of the cholesterol\/statins tsunami?","volume":"47","author":"Blacher","year":"2018","journal-title":"Presse Med"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.toxac.2017.06.003","article-title":"Esteban design: a cross-sectional health survey about environment, biomonitoring, physical activity and nutrition (2014\u20132016)","volume":"29","author":"Balicco","year":"2017","journal-title":"Toxicologie Analytique et Clinique"},{"key":"R14-20230916","first-page":"1769","article-title":"2011\u200aESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur Heart J"},{"issue":"(Suppl 4)","key":"R15-20230916","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: From the systeme national d\u2019information interregimes de l\u2019Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","article-title":"Repositioning of the global epicentre of non-optimal cholesterol","volume":"582","year":"2020","journal-title":"Nature"},{"key":"R19-20230916","first-page":"261","article-title":"Risk factors profile and clinical outcome of ischemic stroke patients admitted in a department of internal medicine and classified by TOAST classification","volume":"25","author":"Pinto","year":"2006","journal-title":"Int Angiol"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/ijcp.12269","article-title":"Metabolic and anti-inflammatory effects of a home-based programme of aerobic physical exercise","volume":"67","author":"Di Raimondo","year":"2013","journal-title":"Int J Clin Pract"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.2174\/1381612822666160510124801","article-title":"Inflammation, endothelial dysfunction and arterial stiffness as therapeutic targets in cardiovascular medicine","volume":"22","author":"Della Corte","year":"2016","journal-title":"Curr Pharm Des"},{"key":"R22-20230916","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R23-20230916","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2020.05.055","article-title":"Current lipid-lowering treatment and attainment of LDL targets recommended by ESC\/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry","author":"De Luca","year":"2020","journal-title":"Int J Cardiol"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijcard.2018.04.068","article-title":"Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors","volume":"268","author":"Breuker","year":"2018","journal-title":"Int J Cardiol"},{"key":"R25-20230916","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.repc.2019.02.009","article-title":"Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: data from the DISGEN-LIPID study","volume":"38","author":"da Silva","year":"2019","journal-title":"Rev Port Cardiol"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.whi.2018.04.008","article-title":"Mapping the Gaps: gender differences in preventive cardiovascular care among managed care members in four metropolitan areas","volume":"28","author":"Bird","year":"2018","journal-title":"Womens Health Issues"},{"key":"R27-20230916","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/17512433.2018.1519391","article-title":"LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature","volume":"11","author":"Ravnskov","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R28-20230916","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"R29-20230916","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/jch.13834","article-title":"Patterns of hypertension management in France in 2015: the ESTEBAN survey","volume":"22","author":"Vall\u00e9e","year":"2020","journal-title":"J Clin Hypertension"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T04:17:29Z","timestamp":1694837849000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":29,"journal-issue":{"issue":"50","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023445","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}